This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McGregor, F. Articles by Harrison, P. R. Search for Related Content PubMed PubMed Citation Articles by McGregor, F. Articles by Harrison, P. R.

Molecular Changes Associated with Oral Dysplasia Progression and Acquisition of Immortality

Potential for Its Reversal by 5-Azacytidine¹

The Beatson Institute for Cancer Research, CRC Beatson Laboratories, Glasgow G61 1BD [F. M., A. M., J. F., J. B., E. K. P., P. R. H.], and Glasgow Dental Hospital and School, Glasgow G2 3JZ [D. H. F., D. G. M.], Scotland

This study has identified molecular changes characteristic of early oral cancer progression. We reported previously that acquisition of the immortal phenotype is an early event in oral cancer development (F. McGregor et al., Cancer Res., 57: 3886–3889, 1997); our current data indicate that about half of oral dysplasia cultures are immortal, and this is associated with loss of expression of retinoic acid receptor (RAR)-ß and the cell cycle inhibitor p16^ink4a (p16), p53 mutations, and increased levels of telomerase/human telomerase reverse transcriptase mRNA. In contrast, increased expression of the epidermal growth factor receptor, known to be a characteristic of oral cancer, does not occur until after the dysplasia stage in squamous cell carcinomas. Acquisition of invasive properties as judged by an in vitro Matrigel invasion assay also does not occur until the carcinoma stage and is further increased in metastases. Interestingly, one atypical mortal dysplasia with a considerably extended life span has lost expression of RAR-ß and p16, but it still expresses only wild-type p53 (albeit at a higher level than normal) and has not activated telomerase. RAR-ß and/or p16 re-expression can be induced by treatment with 5-aza-2-deoxycytidine (Aza-C) in some immortal dysplasias, and this has been shown to be due to silencing of gene expression by promoter methylation. Aza-C treatment also down-regulated telomerase activity and human telomerase reverse transcriptase mRNA. Interestingly, with one dysplasia, Aza-C was able to reverse its immortal phenotype, as judged by morphological criteria and expression of the senescence-associated acid ß-galactosidase activity during terminal growth arrest; this immortal dysplasia was the only one in which Aza-C treatment not only down-regulated telomerase activity but also induced re-expression of both RAR-ß and p16. The possibility of reversing the immortal phenotype of some dysplasias by Aza-C may be of clinical usefulness.

This article has been cited by other articles:

				J. Friedman, L. Nottingham, P. Duggal, F. G. Pernas, B. Yan, X. P. Yang, Z. Chen, and C. Van Waes Deficient TP53 Expression, Function, and Cisplatin Sensitivity Are Restored by Quinacrine in Head and Neck Cancer Clin. Cancer Res., November 15, 2007; 13(22): 6568 - 6578. [Abstract] [Full Text] [PDF]

				K. Gaballah, A. Hills, D. Curiel, G. Hallden, P. Harrison, and M. Partridge Lysis of Dysplastic but not Normal Oral Keratinocytes and Tissue-Engineered Epithelia with Conditionally Replicating Adenoviruses Cancer Res., August 1, 2007; 67(15): 7284 - 7294. [Abstract] [Full Text] [PDF]

				K. D. Hunter, J. K. Thurlow, J. Fleming, P. J.H. Drake, J. K. Vass, G. Kalna, D. J. Higham, P. Herzyk, D. G. MacDonald, E. K. Parkinson, et al. Divergent routes to oral cancer. Cancer Res., August 1, 2006; 66(15): 7405 - 7413. [Abstract] [Full Text] [PDF]

				S. M. Lippman, J. Sudbo, and W. K. Hong Oral Cancer Prevention and the Evolution of Molecular-Targeted Drug Development J. Clin. Oncol., January 10, 2005; 23(2): 346 - 356. [Abstract] [Full Text] [PDF]

				S.-i. Maruya, J.-P. J. Issa, R. S. Weber, D. I. Rosenthal, J. C. Haviland, R. Lotan, and A. K. El-Naggar Differential Methylation Status of Tumor-Associated Genes in Head and Neck Squamous Carcinoma: Incidence and Potential Implications Clin. Cancer Res., June 1, 2004; 10(11): 3825 - 3830. [Abstract] [Full Text] [PDF]

				E. M. Youssef, D. Lotan, J.-P. Issa, K. Wakasa, Y.-H. Fan, L. Mao, K. Hassan, L. Feng, J. J. Lee, S. M. Lippman, et al. Hypermethylation of the Retinoic Acid Receptor-{beta}2 Gene in Head and Neck Carcinogenesis Clin. Cancer Res., March 1, 2004; 10(5): 1733 - 1742. [Abstract] [Full Text] [PDF]

				L. Kopelovich, J. A. Crowell, and J. R. Fay The Epigenome as a Target for Cancer Chemoprevention J Natl Cancer Inst, December 3, 2003; 95(23): 1747 - 1757. [Abstract] [Full Text] [PDF]

				I. Horikawa and J. C. Barrett Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms Carcinogenesis, July 1, 2003; 24(7): 1167 - 1176. [Abstract] [Full Text] [PDF]

				W. Shi, A. Hoeflich, H. Flaswinkel, M. Stojkovic, E. Wolf, and V. Zakhartchenko Induction of a Senescent-Like Phenotype Does Not Confer the Ability of Bovine Immortal Cells to Support the Development of Nuclear Transfer Embryos Biol Reprod, July 1, 2003; 69(1): 301 - 309. [Abstract] [Full Text] [PDF]

				J. Brown, J. O'Prey, and P.R. Harrison Enhanced sensitivity of human oral tumours to the flavonol, morin, during cancer progression: involvement of the Akt and stress kinase pathways Carcinogenesis, February 1, 2003; 24(2): 171 - 177. [Abstract] [Full Text] [PDF]

				K. E. Gordon, H. Ireland, M. Roberts, K. Steeghs, J. A. McCaul, D. G. MacDonald, and E. K. Parkinson High Levels of Telomere Dysfunction Bestow a Selective Disadvantage During the Progression of Human Oral Squamous Cell Carcinoma Cancer Res., January 15, 2003; 63(2): 458 - 467. [Abstract] [Full Text] [PDF]

				S. M. Lippman and W. K. Hong Cancer Prevention Science and Practice Cancer Res., September 15, 2002; 62(18): 5119 - 5125. [Full Text] [PDF]